about
Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug TargetsPCSK6-mediated corin activation is essential for normal blood pressureEffects of the combination of microfracture and self-assembling Peptide filling on the repair of a clinically relevant trochlear defect in an equine modelDelivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels.Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis PainTherapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis.CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy.Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis.Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis.Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.TRPC5 Does Not Cause or Aggravate Glomerular Disease.What is new in pain modification in osteoarthritis?Peripheral Mechanisms Contributing to Osteoarthritis Pain.An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2.Can we target CCR2 to treat osteoarthritis? The trick is in the timing!An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis
P50
Q26822238-C3B04D3C-7044-4D77-B34D-BD660FF0B8ABQ28266080-A6E8E1FE-EC5E-4BE8-A78E-BD94073281A4Q34264401-832FD30C-0FC4-43A4-968D-26C892771127Q35098374-63ABFB8B-AF1C-4E9C-AC02-4599ECE7B6BBQ35893758-79DFC3B1-C88A-4EBF-A3E3-6EF471A0F6E0Q36129918-DF59F1C8-4339-4815-9411-455127C465C5Q36552031-A03BCFF4-BBAA-4B78-AAA2-B4B51F0C1CB3Q37711818-01874B23-6E87-493B-AC89-0D38829C19B1Q38817280-F2859CE9-2F48-4F73-A017-87E3EE922C6DQ38852117-0C8188CF-687C-426A-B894-222FA6ED9E06Q40098254-790235AA-B6E6-4091-8D8D-65A4D786352EQ47717163-F25B60B0-EDB7-4B6E-9138-00F54FD58A06Q47735658-7E7639F8-7E8D-4F8E-8FFE-7D6BCDCB6ED0Q48526597-AC0184FB-B7A5-47BA-B980-2D77938ECD1BQ52685598-212383A7-E0E8-4EEB-9DB3-E66A3D0F2FF1Q52725144-74194C37-026A-4917-BD16-E3486A993A97Q55307134-BE549B8A-1EF2-4B07-B659-AFF059E18F68Q90707220-B0F8648E-0CA2-4818-B015-C1DA42B9BA6A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rachel E Miller
@nl
Rachel E Miller
@sl
Rachel E. Miller
@en
Rachel E. Miller
@es
type
label
Rachel E Miller
@nl
Rachel E Miller
@sl
Rachel E. Miller
@en
Rachel E. Miller
@es
prefLabel
Rachel E Miller
@nl
Rachel E Miller
@sl
Rachel E. Miller
@en
Rachel E. Miller
@es
P106
P108
P1153
36662471600
P21
P31
P496
0000-0002-4486-5757